Philip Arlen, MD Joins Neogenix Oncology As President and Chief Medical Officer
Neogenix Oncology, Inc. (Neogenix) announced today that Philip M. Arlen, MD, was elected to the Board of Directors at its August 2008 meeting. The company also announced that Dr. Arlen had accepted the company’s offer to become President and Chief Medical Officer, effective immediately.
Dr. Philip M. Arlen is a Board Certified Medical Oncologist with extensive clinical experience in Medical Oncology as well as cancer research in the field of Tumor Immunology. Prior to joining Neogenix, he was Director of the Clinical Research Group, Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI) in Bethesda, Maryland. He is recognized internationally for his work in the field having received numerous awards and has published over 75 peer reviewed scientific papers on topics related to cancer immunology. He has been invited to present as a panelist and keynote speaker at major medical meetings around the world. With more than 10 years of clinical oncology research experience, Dr. Arlen will initially focus on the clinical development program for the company’s novel monoclonal antibody, NPC-1C, which is intended for the treatment of pancreatic cancer. In addition, he will play an integral role in the R&D effort overseeing the translation of Neogenix Oncology’s pipeline candidates into potential clinical products.
“We are delighted that Dr. Arlen has joined Neogenix as a key member of our leadership team,” said Chief Operating Officer, Thomas Lytle. “With his extensive knowledge and clinical experience, he will make a significant contribution toward guiding our development programs and helping the company to develop its portfolio of innovative cancer therapeutics and diagnostics.”
About Neogenix Oncology Inc.
Founded in 2004, Neogenix Oncology, Inc., is a research-driven biopharmaceutical company that develops and commercializes innovative diagnostics and therapeutics for the management of serious and difficult to treat cancers. Neogenix’s pipeline is derived in part from the Hollinshead library of clinically tested vaccines, with the potential to develop products for a wide range of cancers, including pancreas, colorectal, prostate, lung, ovarian, squamous, and others. The company conducts its research and development work in its laboratories in Great Neck, NY and in Rockville, MD. For more information, please visit the company’s website at www.neogenixoncology.com.
This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.